摘要
目的探讨高强度聚焦超声(HIFU)消融联合CAO化疗对中晚期肝母细胞瘤患儿的治疗效果。方法研究对象为2018年1月至2021年1月本院收治的68例中晚期肝母细胞瘤患儿,随机分为观察组与对照组,各34例。所有患儿均接受CAO化疗,观察组在化疗基础上接受HIFU消融。对比两组治疗有效率、免疫功能、肿瘤标志物和不良反应,并对比治疗后3年的生存率。结果观察组和对照组的治疗总有效率分别为70.59%(15/34)和44.12%(24/34),观察组比对照组提高(P<0.05);观察组治疗后的CD3^(+)、CD4^(+)分别为(51.71±5.86)%和(30.84±4.03)%,高于对照组(P<0.05);观察组治疗后的CD8^(+)为(28.16±3.01)%,CD8^(+)和肿瘤标志物水平均低于对照组(P<0.05);观察组和对照组不良反应总发生率分别为20.59%和23.53%,差异无统计学意义(P>0.05);观察组和对照组3年内PFS分别为(24.59±4.68)月和(18.26±5.76)月,生存率分别为79.41%(27/34)和47.06%(16/34),观察组均高于对照组(P<0.05)。结论联合HIFU和CAO化疗治疗中晚期肝母细胞瘤患儿,有助于提高临床疗效,改善患儿免疫功能,提高生存率。
Objective To evaluate the therapeutic effects of High-Intensity Focused Ultrasound(HIFU)ablation combined with CAO chemotherapy in pediatric patients with advanced hepatoblastoma.Methods From January 2018 to January 2021,68 pediatric patients with advanced hepatoblastoma were enrolled and divided into two groups:a control group and an observation group,with 34 patients in each group.The control group was treated with CAO chemotherapy,whereas the observation group underwent a combination of CAO chemotherapy and HIFU ablation.The clinical effectiveness,immune function alterations,tumor marker levels,and adverse reactions pre-and post-treatment between two groups were compared.Additionally,a three-year follow-up was performed to evaluate the prognosis.Results The total effective rates of the treatment in the observation group and control group were 70.59%(15/34)and 44.12%(24/34),respectively,with a significant improvement in the observation group(P<0.05).After treatment,the CD3^(+)and CD4^(+)levels in the observation group were(51.71±5.86)%and(30.84±4.03)%,respectively,which were significantly higher than those in the control group(P<0.05).The CD8^(+)level in the observation group was(28.16±3.01)%,and both CD8^(+)and tumor marker levels were significantly lower than those in the control group(P<0.05).The total incidence of adverse reactions in the observation and control groups was 20.59%and 23.53%,respectively,with no statistically significant difference(P>0.05).The progression-free survival(PFS)over 3 years in the observation and control groups was(24.59±4.68)and(18.26±5.76)months,respectively,and the survival rates were 79.41%(27/34)and 47.06%(16/34),significantly higher than the control group(P<0.05).Conclusion The integration of HIFU ablation with CAO chemotherapy in the treatment of pediatric patients with advanced hepatoblastoma helps to enhance clinical efficacy,improve immune function,and increase survival rates.
作者
陈震
李静娴
CHEN Zhen;LI Jing-xian(Department of Ultrasound,Hospital of Xinyang Normal University,Xinyang 464000,China;Department of Internal Medicine,Hospital of Xinyang Normal University,Xinyang 464000,China)
出处
《肝脏》
2025年第11期1572-1576,共5页
Chinese Hepatology
基金
河南省医学科技攻关计划联合共建项目(LHGJ20210020)。
关键词
高强度聚焦超声
CAO化疗
中晚期肝母细胞瘤
临床疗效
生存率
High-intensity focused ultrasound
CAO chemotherapy
Advanced hepatoblastoma
Clinical efficacy,Survival rate
